Fennec Pharmaceuticals is a small stage biotechnology company focused on the development of PEDMARK TM (a unique formulation of Sodium Thiosulfate) for the prevention of ototoxicity from cisplatin in pediatric patients.
PEDMARK is an investigational drug and has not yet been approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority.
Publications & Presentations
Helping the Kids of Today Become the Adults of Tomorrow
Hearing loss is a devastating and life-long impact on quality of life for children that can cause grade setbacks and learning problems. Fennec advocates for a better quality of life.
Fennec News
- August 13th, 2018 Fennec Provides Business Update and Announces Second Quarter 2018 Financial Results
- August 7th, 2018 FENNEC PHARMACEUTICALS RECEIVES POSITIVE OPINION ON THE PEDIATRIC INVESTIGATION PLAN FROM EUROPEAN MEDICINES AGENCY FOR PEDMARK TM AND CONFIRMATION OF ELIGIBILITY FOR A PEDIATRIC USE MARKETING AUTHORIZATION
- June 21st, 2018 Fennec Announces Publication of Pedmark(TM) Siopel 6 Clinical Data in the New England Journal of Medicine